Discoveries/GEDUNIN

✓ X-VAULT VERIFIEDEXPLORATORYNOVELTY: LOW

GEDUNIN

Signaling by ERBB2 candidate

754.0

discovery score

PubMed Studies

Novelty

Low

Signal

Exploratory

Sealed

May 20, 2026

BiohacksAI Hypothesis

Gedunin may modulate the Signaling by ERBB2 pathway based on its molecular target profile in the BiohacksAI corpus. This compound shows biological activity against validated targets with limited prior literature coverage, suggesting an understudied mechanism-of-action with potential research value.

Computational hypothesis based on target graph analysis. Not a confirmed mechanism. Independent experimental validation required.

Mechanism Discovery Graph

High-value target (Tier 3)

Research target (Tier 2)

Standard target

Pathway

Biological Plausibility

The Signaling by ERBB2 pathway is a validated biological target area with established relevance in human disease and health research.

Gedunin shows target overlap with compounds previously characterized in this pathway within the BiohacksAI corpus of 31,590 graph entities and 1.51M PubMed studies.

Low literature coverage (54 studies) relative to target engagement indicates this mechanism may be undercharacterized in current scientific literature — a signal consistent with early-stage discovery candidates.

Novelty Indicators

Literature coverage

54 PubMed studies

Low coverage = higher novelty potential

Discovery score

754.04

target_count × pathway_diversity / log(studies + 2)

Mechanism area

Signaling by ERBB2

Primary biological pathway

Novelty rating

Low

Derived from score + literature coverage

Research Context

◈

Literature coverage

54 PubMed studies indexed at time of discovery

◈

X-Vault timestamp

Sealed May 20, 2026 — cryptographic proof of discovery date and corpus version

◈

Corpus scope

BiohacksAI corpus only — not a comprehensive literature or patent database search

◈

Mechanism area

Signaling by ERBB2 — computationally derived, requires experimental confirmation

This section reflects computational signal strength only. All findings require independent expert validation before any research or commercial use.

Suggested Validation Steps

1Signaling by ERBB2 pathway target binding assay

2Dose-response curve (EC50 determination)

3Cellular viability and selectivity panel

4In vitro ADMET profiling

Validation roadmap is algorithmically derived from pathway context. Full experimental protocol available in Priority Signal discovery reports.

Target Relevance

HSP90AA1

Standard

BRCA1

Research

FASN

Standard

NCOA2

Standard

GMNN

Standard

NPBWR1

Standard

Target tier based on BiohacksAI HIGH_VALUE_TARGETS registry.

Discovery Lineage

Generated byBiohacksAI Discovery Engine

Engine versionDISCOVERY_v1.0

Corpus versioncurrent

Graph entities31,590 compounds analyzed

PubMed coverage1.51M studies

Discovery dateMay 20, 2026 at 02:00 AM UTC

X-Vault Evidence SealXVAULT_v1

Discovery IDDISC-gedunin-20260520-2a83150f

Event Hash—

Chain Hash—

Vault Index#—

Sealed At2026-05-20T02:00:00.775Z

Verify this discovery →↓ Demo PDF (X-Vault sealed)

Demo report — computational hypothesis only. Not validated. For X-Vault verification testing.

Full Discovery ReportLOCKED

🔒

Mechanism hypothesis (expanded)

Detailed molecular mechanism with target confidence scores and binding context

🔒

Complete target mapping

All validated molecular targets with affinity data and evidence levels

🔒

Biological pathway network

Full pathway coverage map with crosstalk and downstream effects

🔒

Graph position + related compounds

Structural neighbors in the BiohacksAI compound graph — potential analogs

🔒

Supporting PMIDs

Curated PubMed references with relevance ranking

🔒

X-Vault sealed PDF

Cryptographically verified 20-30 page discovery report

Interested in this discovery? Contact us for access and licensing details.

All discoveries are computational hypothesis candidates — not confirmed mechanisms. Independent experimental validation is required before any research or commercial use. Organiq Sweden AB · BiohacksAI β